Protein a Resin Market Report 2025

The protein A resin market size has grown strongly in recent years. It will grow from $1.66 billion in 2024 to $1.8 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to increasing biopharmaceutical production, growing adoption of monoclonal antibodies, expanding research and development activities, regulatory emphasis on biopharmaceutical quality, rising prevalence of chronic diseases.

The protein A resin market size is expected to see rapid growth in the next few years. It will grow to $2.66 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to rising biosimilar development, focus on cost-efficiency, increasing investment in bioprocessing facilities, expansion of biopharmaceutical market in emerging economies, growing demand for personalized medicine. Major trends in the forecast period include single-use systems, technological advancements, demand in emerging markets, strategic collaborations and partnerships, focus on sustainable practices.

The anticipated increase in R&D investments within pharmaceutical companies is poised to drive the growth of the protein A resin market. Research and Development (R&D) involve the exploration and creation of new drugs, therapies, technologies, or services aimed at enhancing patient health. Protein A resin is a crucial component in chromatography assays utilized during pharmaceutical development processes. In 2022, Roche Holding AG, a Switzerland-based pharmaceutical company, set a record by spending $16.79 billion on R&D, marking a 3.7% increase from 2021. Similarly, Merck, a US-based pharmaceutical company, elevated its R&D spending by 10% in 2022, reaching $13.54 billion. Consequently, the heightened R&D investments in pharmaceutical firms are fostering the expansion of the protein A resin market.

The rise in healthcare expenditure is anticipated to drive the growth of the protein A resin market in the future. Healthcare expenditure refers to the total amount allocated for healthcare services, goods, and activities within a specific healthcare system or economy over a particular timeframe. Increased healthcare spending facilitates greater investment in research and development related to protein A resin, fostering innovations, enhancing manufacturing processes, improving efficiency, and driving advancements. This investment ultimately boosts production capabilities, ensures product quality, and enhances the availability of this essential component in biopharmaceutical manufacturing. For example, in May 2024, the Office for National Statistics, a UK-based statistics authority, reported that healthcare expenditure in the UK was approximately £292 billion in 2023, indicating a nominal increase of 5.6%. Furthermore, long-term health and social care spending rose by 2.8% in real terms in 2022. Therefore, the increasing healthcare expenditure is fueling the growth of the protein A resin market.

Major companies in the protein A resin market are prioritizing product innovation, such as high-performance affinity protein A resin, to enhance purification efficiency, lower production costs, and improve overall yield in biopharmaceutical manufacturing. High-performance affinity protein A resin is a specialized chromatography medium designed for the efficient purification of antibodies and other proteins from complex biological mixtures. For example, in July 2024, Purolite, Ltd., a US-based developer, manufacturer, and supplier of resins, launched DurA Cycle A50, a new affinity protein A resin aimed at enhancing downstream purification in the biologics sector. This innovative resin features an extended lifespan, reduced ligand leakage, and high performance, offering a cost-effective solution for antibody purification. The product launch addresses key industry challenges, such as reducing costs and ensuring supply chain security through dual sourcing, thereby increasing efficiency for customers.

Major companies in the protein resin market are focusing on developing high-reliability technologies, including polymer technology, to boost productivity and tackle the specific challenges of purifying complex biomolecules in biopharmaceutical manufacturing. Polymer technology in protein A resin enhances the performance and stability of resins in chromatography processes for antibody purification, improving binding capacity, chemical resistance, and longevity. For instance, in September 2024, JSR Life Sciences, a US-based company that develops and manufactures various biomedical materials, launched Amsphere A+, a next-generation protein A chromatography resin designed to improve antibody drug purification. This new resin offers superior binding capacity, stability, and efficiency compared to its predecessor, Amsphere A3. The innovation aims to support the increasing complexity of antibody drug production, particularly for bispecific antibodies and antibody-drug conjugates, utilizing a proprietary protein ligand and advanced polymer technology to enhance production efficiency.

In April 2023, Sino Biological, a China-based company specializing in recombinant protein production and antibody development, acquired SignalChem Biotech Inc. for $48 million. This acquisition aims to enhance Sino Biological’s expertise in bioactive enzyme production, which is crucial for advancing drug discovery and development, and to expand its product range and research services. By leveraging specialized enzyme platforms, Sino Biological seeks to better serve the global life sciences community. SignalChem Biotech Inc. is a Canada-based company focused on the research, development, and production of innovative and high-quality human recombinant cell signaling products.

Major companies operating in the protein A resin market include GenScript Biotech Corporation, Agilent Technologies Inc., Repligen Corporation, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Abcam plc, Novasep Holdings SAS, GE Healthcare Technologies Inc., Merck KGaA, Tosoh Bioscience LLC, Purolite Corporation, Kaneka Corporation, JSR Life Sciences Corporation, Danaher Corporation, Avantor Inc., Global Life Sciences Solutions USA, EMD Millipore Corp., Bio-Works Technologies AB, Avantor Performance Materials LLC, Avacta Life Sciences Limited, Purolite Lifesciences.

North America was the largest region in the Protein A Resin market in 2024. Europe is expected to be the fastest-growing region in the protein A resin market report during the forecast period. The regions covered in the protein a resin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the protein a resin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Protein A resin is a type of chromatography resin widely utilized in protein purification processes, particularly for the purification of antibodies and monoclonal antibody products.

The main types of protein A resins include natural protein A and recombinant protein A. Natural protein A is a high-efficiency chromatography medium produced in the bacteria Staphylococcus aureus. The matrix types involved in protein A resins are agarose-based protein A, glass/silica-based protein A, and organic polymer-based protein A. These resins find applications in various processes, including antibody purification and immunoprecipitation. Protein A resins are commonly employed by biopharmaceutical manufacturers, clinical research laboratories, and academic institutes.

The protein A resin market research report is one of a series of new reports that provides protein A resin market statistics, including protein A resin industry global market size, regional shares, competitors with a protein A resin market share, detailed protein A resin market segments, market trends, and opportunities, and any further data you may need to thrive in the protein A resin industry. This protein A resin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The protein A resin market consists of sales of fiber-based fibro prismA units, agarose-based protein A, and ion exchange chromatography resins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.